EMA accelerates assessment of Revolution Medicines daraxonrasib
Revolution Medicines announced that European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, has started a phased review of data on daraxonrasib, the company's investigational RAS multi-selective inhibitor. A phased review aims to accelerate the assessment of a medicine by evaluating the dat